Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

Shares of Septerna, Inc. (SEPN) have gained 57.8% over the past four weeks to close the last trading session at $9.42, but there could still be a solid upside left in the stock if short-term price ...

Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market.

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

The deal is big for a Bay Area drug industry in need of big wins. Septerna shares surged 55% in early trading. Peninsula startup nets Nobel winner, $100M to change drug discovery How taming a ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...

In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands against the other stocks. We previously covered 10 stocks with at least $ 20 million in insider spending ...

Septerna, Inc. aims to raise $100 million in an IPO to advance its clinical-stage biopharma treatments for endocrine diseases, with SEP-786 in Phase 1 trials. The hypoparathyroidism treatment ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...

“This collaboration provides a significant opportunity to create multiple potentially groundbreaking oral medicines, while also providing Septerna with substantial resources and operational ...